We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Wrangling proteins gone wild
News

Wrangling proteins gone wild

Wrangling proteins gone wild
News

Wrangling proteins gone wild

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Wrangling proteins gone wild"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

New software programs should help identify potential avenues for improved drug treatments for Alzheimer's -


Proteins sometimes run amuck, distorting the useful genetic and biological material they contain. Mutations in specific amino acids can cause long strands of proteins to curl in on themselves and refuse to break apart. These strands, known as amyloid fibrils, can be extremely toxic and are usually harmful. They attach to organs like the brain and pancreas, preventing them from functioning as they should and are responsible for diseases as seemingly different as diabetes and Alzheimer’s, to name just a couple. Developing effective medications to treat these diseases, and cause the fibrils to dissolve typically involves biochemists in a lengthy and expensive process of trial and error.


Billions of choices

But now McGill University researchers in Montreal, Canada, led by Prof. Jérôme Waldispühl of the School of Computer Science, have created a suite of computer programs that should speed up the process of drug discovery for diseases of this kind. The programs are designed to scan the fibrils looking for weak spots. The idea is to then design helpful genetic mutations to dissolve the bonds that hold the fibrils together - a bit like finding the right strand of wool to tug on to unravel a whole knotted ball. It’s potentially a gargantuan task, because looking for the mutations that will prove useful in drug development involves exploring millions of possible structural combinations of genetic material.


But for the Fibrilizer, as McGill has dubbed its suite of computer tools, a name that hints at the super heroic nature of the programs they have developed, the task is of a very different order. “Within the space of a week, by using our programs and a supercomputer, we were able to look at billions of possible ways to weaken the bonds within these toxic protein strands. We narrowed it down to just 30 - 50 possibilities that can now be explored further,” says Mohamed Smaoui, a McGill postdoctoral fellow and the first author on three recent papers on the research. “Typically biochemists can spend months or years in the lab trying to pinpoint these promising mutations.”


Supercomputers to the rescue

The researchers tested their program on a medical compound that scientists have been trying to improve for the last couple decades. The compound is administered as part of a drug that is used by diabetes patients to boost the performance of insulin and is sold under the name Symlin. The synthetic compound is based on a version of the protein amylin, yet is known to be toxic to the pancreas over the long-term, creating amyloid fibrils. The McGill team were able to use Fibrilizer to pinpoint a limited number of possible genetic modifications to the compound that would act to reduce its toxicity.


protein fibrils

Credit: McGill University

Jérôme Waldispühl, the lead researcher on the papers, believes that computational research of this kind will play an increasingly important role in drug discovery in the future. “Computers are transforming the way that drugs are being developed,” says Waldispühl. “Amyloid research has accelerated in the last 10 years. But it may prove to be the key to finding better medications for a whole range of systemic and neurodegenerative diseases, from arthritis to Parkinson’s. Without supercomputers and programs of this kind, this research would be much more time-consuming and expensive.”


Note: Material may have been edited for length and content. For further information, please contact the cited source.

McGill University   press release


Publication

Smaoui MR, Ortand H, Waldispühl1 J. Probing the binding affinity of amyloids to reduce toxicity of oligomers in diabetes.   Bioinformatics, Published Online March 15 2015. doi: 10.1093/bioinformatics/btv143


Advertisement